Since the combination of VEGF-trap with anti-PD-1 was found to be safe in patients with cancer (Tyan et al., 2021), a potential future combination regimen may involve the co-administration of 4T-Trap with VEGF-trap and ICB. The gene discussed is PDCD1; the disease is cancer.